

GPCI-P10-071
09/016,869

October 18, 1993; and is a continuation-in-part of 07/991,997 filed December 17, 1992, now abandoned; which is a continuation-in-part of 07/963,308 filed October 16, 1992, now abandoned.

The amendments to the specification presented above incorporate changes as indicated by the marked-up versions below.

This application is a continuation of application number 08/893,274, filed on July 15, 1997, now U.S. Patent No. 5,968,821; which is a continuation of 08/306,511 filed September 14, 1994-9/14/94, now U.S. Patent No. 5,962,316; which is a continuation-in-part of 08/248,812 filed May 25, 1994-5/25/94, now U.S. Patent No. 5,889,169; which is a continuation-in-part of 08/154,915 filed November 18, 1993-11/18/93; which is a National Stage Application of claims priority to PCT/US93/09945, filed October 18, 1993-10/18/93; and is a continuation-in-part of 07/991,997 filed December 17, 1992-12/17/92, now abandoned (abandoned); which is a continuation-in-part of 07/963,308 filed October 16, 1992-10/16/92, now abandoned.

In the claims:

Please cancel claims 96 and 97 without prejudice. Please amend claims 91, 92, 94, 95, 98, 103, 104, 106, 108, and 111. For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

91. (Amended) An isolated antibody specifically reactive with a 16 kD protein that co-precipitates with CDK4 from cell lysates of SV40-transformed WI38 cells in the presence of an anti-CDK4 antibody, wherein the molecular weight of the 16 kD protein is identified by polyacrylamide gel electrophoresis (PAGE) under denaturing conditions.

92. (Amended) An isolated antibody specifically immunoreactive with a 16 kD protein that co-precipitates with CDK4 from cell lysates of SV40-transformed WI38 cells in the presence of an anti-CDK4 antibody, wherein the molecular weight of the 16 kD protein is identified by PAGE under denaturing conditions.

93. (Reiterated) The antibody of claim 92, wherein the antibody is a monoclonal antibody.